European Biopharmaceutical Enterprises Announces New Board
June 16, 2016.
European Biopharmaceutical Enterprises, EBE, has announced its Board of Directors for the term 2016â2018, following the EBE and EFPIA (European Federation of Pharmaceutical Industries and Associations) Annual Meetings this week.
EBE members appointed a 13-strong C-level board headed by Eduardo Bravo, CEO of TiGenix, who previously served as EBE Vice-President. Mr. Andrea Chiesi - currently Vice President of Holostem Advanced Therapies and Director R&D Project Portfolio Management at Chiesi Farmaceutici - will support Mr Bravo as EBE Vice President. Didier Malherbe, Vice President of Public Affairs, UCB and Managing Director UCB Belgium, was re-elected as Treasurer of EBE.
The full EBE board is illustrated below.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
